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Background:  Atypical cutaneous lymphoid infiltrates are challenging lesions in dermatopathology. We 
present a summary of the literature regarding kappa and lambda immunohistochemistry (IHC) and in situ 
hybridization (ISH) in the evaluation of atypical cutaneous or mucosal lymphoid infiltrates. 
Methods:  Relevant articles from 1967-2018 in the English language were identified and summarized.  In 
the absence of larger studies, case series of n≥3 were included. 
Results:  63 articles assessing kappa and lambda IHC and/or ISH were identified.  Most focused on 
marginal zone lymphomas.  Other lymphomas included follicle center lymphoma, diffuse large B-cell 
lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, 
lymphoplasmacytic lymphoma, plasmablastic lymphoma, multiple myeloma, monoclonal gammopathy of 
undetermined significance, and polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin 
changes (POEMS).  Non-neoplastic lesions included reactive lymphoid hyperplasia, cutaneous 
plasmacytosis, connective tissue disease, IgG4-related disease, acrodermatitis chronic atrophicans, Zoon’s 
balanitis, dermatitides, and infiltrates around epithelial dysplasias/neoplasias. 
Conclusion:  Kappa and lambda IHC and ISH are useful tools in the evaluation of cutaneous B-cell 
lymphomas and plasma cell neoplasms.  The literature supports that the detection of light chain restriction 
by IHC and ISH is one of the most useful findings in the differential diagnosis of reactive lymphoid 
hyperplasia versus B-cell lymphoma with plasmacytic differentiation. 








This article is protected by copyright. All rights reserved.
 
 
This article is protected by copyright. All rights reserved.
Introduction 
Atypical cutaneous lymphoid infiltrates are diagnostically challenging lesions.  They often require a 
combination of clinical, histopathologic, immunophenotypic and genetic features to arrive at an accurate 
diagnosis.  Each of these features include pitfalls in interpretation and application, as reactive processes 
can mimic lymphomas both clinically and histopathologically and may also include a clonal B cell and/or 
T cell population.  Kappa and lambda immunohistochemistry (IHC) and in situ hybridization (ISH) are 
useful tools in the evaluation of cutaneous B-cell lymphomas and plasma cells neoplasms.  These studies 
target kappa or lambda light chains in plasma cells and, to a lesser extent, B cells.  IHC for kappa and 
lambda on formalin-fixed, paraffin-embedded (FFPE) tissues is variably reported as cytoplasmic1,2 or 
cytoplasmic and membranous3,4 in the literature, and may depend on the antibody and technique used.  In 
particular, enzyme digestion and heat-induced epitope retrieval techniques have been used to enhance the 
performance of IHC staining of neoplastic B cells in low grade B-cell lymphomas.  In addition, the 
distinction between cytoplasmic and membranous staining may be difficult to discern.1  Frozen section 
IHC analysis of kappa and lambda detects both cytoplasmic and membranous light chain.1  ISH detects 
cytoplasmic mRNA. Flow cytometry (FC) may also be used to assess kappa and lambda ratios.  FC 
routinely detects surface immunoglobulin and may also detect cytoplasmic immunoglobulin following a 
permeablization procedure.      
Kappa and lambda expression is most abundant and therefore most easily detected in plasma cells, which 
lose surface immunoglobulin.5,6  As such, only light chain restricted plasma cells or cells with 
lymphoplasmacytoid differentiation are best detected with IHC or ISH.2,7,8  While the precise ratios of 
kappa and lambda expressing cells that signify monotypia have not been defined, when a marked 
predominance of kappa or a predominance of lambda light chain expression is identified, a clonal 
population is presumed (kappa:lambda of ≥8-108-15 or <0.1-0.38,10-18).  In contrast, non-neoplastic 
populations of B cells and plasma cells characteristically include a mixture of kappa and lambda-positive 
cells, often with a slight kappa predominance (kappa:lambda of approximately 1-4:1-2).9,10,19-21  As part of 
the American Society of Dermatopathology (ASDP) Appropriate Use Committee (AUC) Task Force, 
lymphoproliferative subgroup, three practicing, board-certified dermatopathologists working in academic 
medical centers (N.C., A.H.) or a hybrid academic/private practice (U.S.), assessed the evidence-based, 
peer-reviewed literature from 1967 to 2018 on the utility of kappa and lambda IHC as compared to ISH in 
the evaluation of cutaneous B-cell lymphomas, plasma cell neoplasms and atypical cutaneous lymphoid 
infiltrates. This paper summarizes the literature for assessing light chain restriction in mucosal and 
cutaneous infiltrates by IHC and ISH and also briefly discusses other technologies.  
 
Materials and Methods 
Literature Review 
PubMed was searched for relevant articles from 1967-2018 in the English language.  Search terms include 
combinations of “cutaneous,” “skin,” “marginal zone lymphoma,” “MALT lymphoma,” 
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“immunocytoma,” “amyloidoma,” “plasmacytoma,” “follicular lymphoid hyperplasia,” “follicle center 
lymphoma,” “diffuse large B-cell lymphoma,” “large B-cell lymphoma, leg type,” “chronic lymphocytic 
leukemia/small lymphocytic lymphoma,” “multiple myeloma,” “plasmablastic lymphoma,” “IgG4,” 
“Zoon’s balanitis/vulvitis,” “light chain,” “in situ hybridization,” “cutaneous pseudolymphoma,” “skin 
pseudolymphoma,” “cutaneous plasmacytosis,” “kappa,” “lambda,” and “immunohistochemistry.”  In the 
absence of larger studies, case series of n≥3 were included. 
 
Results  
63 relevant articles assessing kappa and lambda IHC or ISH in the evaluation of an atypical cutaneous or 
mucosal lymphoid infiltrate were identified (Table 1, Supplementary Table).5,9-18,22-73  44 papers evaluated 
IHC exclusively,10,11,13,15,17,22-29,31,32,34,35,37,40,42,45,46,48-50,52-55,57-69,71-73 while 9 papers evaluated ISH 
exclusively,9,16,18,30,43,44,47,70,73 and 10 papers examined both IHC and ISH.5,12,14,33,36,38,39,41,51,56  Two studies 
examined frozen tissue only,58,65 5 studies used frozen and FFPE tissue,25,35,49,61,62 one study used 
formalin- or glutaraldehyde-fixed, paraffin-embedded tissue,28 one study used formalin or B5-fixed, 
paraffin-embedded tissue,50 one study used formalin or Zenker’s fixed paraffin-embedded tissue,71 one 
study used formalin and B5-fixed paraffin-embedded tissue and frozen tissue,67 three studies did not 
specify fixation,47,70,73 and the remainder utilized FFPE tissue.5,9-18,22-24,26,27,29-34,36-48,51-57,59,60,64,66,68,69,72  
Most studies examined marginal zone lymphomas (MZL) of skin and mucosa (i.e. extranodal marginal 
zone lymphomas of mucosa associated lymphoid tissue), either alone or in combination with other 
lymphomas or atypical lymphoid infiltrates (39 papers; Figure 1A-F).5,9,11,13,14,16-18,22-24,28-
33,35,38,39,41,43,44,49,50,52-54,58,60-64,66,68,69,72,73  16 papers exclusively examined primary cutaneous marginal zone 
lymphoma with kappa and lambda IHC/ISH, including lesions termed immunocytomas, amyloidomas, 
primary cutaneous plasmacytomas and cutaneous follicular lymphoid hyperplasia with monotypic plasma 
cells.13,14,18,24,29,30,32,43,44,52-54,66,68,69,73  Other papers focused on extranodal marginal zone secondarily 
involving the skin or mucosa and other sites,9 or a combination of primary and secondary 
MZLs.11,23,24,28,31,50,62-64 The MZLs studied included plasma cell rich variants, in which plasma cells made 
up 50% or more of neoplastic cells.11,18,23,24,28,31,35,41,43,50,52,54,62,63  Other lymphomas examined using kappa 
and lambda IHC or ISH included the relatively skin specific entities follicle center lymphoma 
(FCL)5,16,23,28,37,41,56,61,64-66 and primary cutaneous diffuse large B-cell lymphoma, leg type (DLBCL-
LT).5,22,37,41,61 One study examined primary and secondary cutaneous “T-cell-rich B-cell lymphomas.”67 
Secondary cutaneous involvement by systemic B-cell lymphomas were also studied, included chronic 
lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL),5,16,25,26,39,55 mantle cell lymphoma 
(MCL),23,28 lymphoplasmacytic lymphoma,23,28 plasmablastic lymphoma,41 “immunoblastic” 
lymphoma,41,72 and cutaneous B-cell lymphoma not further classified.66  Some studies included diffuse 
large B-cell lymphomas that were not fully subtyped.16,23,28  One paper examined a variety of systemic 
plasma cell dyscrasias in the skin (multiple myeloma, monoclonal gammopathy of undetermined 
significance, Waldenstrom macroglobulinemia, and polyneuropathy, organomegaly, endocrinopathy, 
monoclonal protein, skin changes (POEMS)).42  Seven other papers examined cutaneous involvement by 
multiple myeloma.5,15,28,41,48,70,71  Eleven papers examined kappa and lambda restriction in mucosal 
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lesions, including oral, ocular and genital mucosa.9,10,23,28,33,35,45,50,56,58,60 When histopathologic features 
were fully described, plasma cells were inconspicuous to absent in FCL,28,37,41 MCL,28 DLBCL,37,41 and 
most cases of CLL/SLL,25,26,39,55 and light chain restriction was recognized in some cases by weak 
staining of B cells.31,41  Non-neoplastic infiltrates examined using kappa and lambda IHC and ISH 
included reactive lymphoid hyperplasia (cutaneous lymphoid hyperplasia, atypical lymphoid hyperplasia, 
“lymphocytoma cutis”),5,16,17,22,24,27,28,41,45,56,60,64,72, cutaneous plasmacytosis,12,34,36,40,46 connective tissue 
disease,9,47,72 IgG4-related disease,33,51  acrodermatitis chronic atrophicans,57 Zoon’s balanitis,10 allergic 
dermatitis,72 rosacea,72 lichen planus,72 syphilis,72 and plasma-cell-rich infiltrates around epithelial 




Cutaneous lymphomas are often diagnostically challenging because they show significant clinical and 
histopathological overlap with reactive processes and usually contain numerous reactive inflammatory 
cells.21  Further complicating matters, some regions of the body, such as the ocular, oral and genital 
mucosa and mucocutaneous junctions, normally have increased numbers of reactive lymphoid and plasma 
cells.10 Moreover, overt lymphoma, especially MZL, may progress from pre-existing, non-neoplastic 
lymphoid infiltrates.9,33,53,58,74 Small biopsy size, crush artifact, fixation issues, and distortion of lymphoid 
architecture by collagen and adnexal structures are common complications and may further hamper 
interpretation.  Often a combination of clinical, morphologic, immunophenotypic and genetic findings are 
necessary to render the appropriate diagnosis.  Kappa and lambda ISH and IHC are often used in the 
evaluation of an atypical cutaneous lymphoid infiltrate, as light chain restriction in B cells or plasma cells 
is highly suggestive of a clonal neoplastic process.   
B cells express surface light chain starting in the pre-B-cell stage.  As they mature to plasma cells, B cells 
increase production of light chain mRNA.  Plasma cells have abundant cytoplasmic light chain, but lose 
surface light chain.  ISH detects KAPPA and LAMBDA mRNA within the cytoplasm of plasma cells and 
some B cells.  In contrast, IHC recognizes cellular and extracellular kappa and lambda proteins.  Flow 
cytometry (FC) also detects light chain restriction.  It is often used to detect surface light chain, but can be 
used to detect cytoplasmic light chain following a permeabilization procedure. ISH has been found to be 
superior to IHC in some studies.6,8  In the paper by Rimsza et al., for example, the sensitivity of 
chromogenic ISH (CISH) was found to be 89%, while specificity was found to be 99%, when flow 
cytometry or IHC was used as a reference method.6 In some conditions, IHC may display high 
background due to serum light chains, reactivity with follicular dendritic cells, or non-specific staining, 
and may show low sensitivity for one or both light chains.1,7,8,41  In contrast, many laboratories find that 
ISH is less likely to show background as it detects intracellular components, and has been reported to be 
more likely to recognize light chain restriction within B cells, depending on their stage of 
differentiation.6,8  While ISH may be better at detecting light chain restriction within B cells than IHC, 
similar to IHC, ISH is best able to detect light chain restriction in plasma cells and cells with plasmacytic 
differentiation,41 though newer techniques such as bright field ISH may help in the detection of light chain 
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restriction in B cells.16  Practically speaking, laboratories may find they have better outcomes with IHC or 
ISH based upon a variety of factors, including experience and platform, among other causes. Furthermore, 
ISH is ideally performed with separate positive and negative controls on the tissue of interest, which can 
be difficult for small biopsies. 
In the papers evaluated here, both kappa and lambda IHC and ISH were useful in the evaluation of 
atypical cutaneous lymphoid infiltrates.  Detection of light chain restriction in plasma cells or B cells 
supported a clonal B-cell and/or plasma cell population and a neoplastic process over an atypical reactive 
process.  This was especially true for neoplasms with plasmacytic differentiation; however, some 
lymphomas without overt plasmacytic differentiation, including a subset of CLL/SLL,5,25,26,55 
FCL16,28,37,41,61,64,65 and DLBCL5,16,37,41 also revealed light chain restriction.  While plasmacytic 
differentiation is expected for plasma cell neoplasms, lymphoplasmacytic lymphoma and many MZLs, 
CLL/SLL may show plasmacytic differentiation,25,39 and a variety of other B-cell lymphomas rarely show 
an associated neoplastic plasma cell component.75   
A handful of studies examined kappa and lambda IHC and ISH in cutaneous involvement by a plasma 
cell dyscrasia.  Magro et al. examined scleroderma-like tissue reactions in 10 patients with a preceding, 
concurrent or subsequent diagnosis of plasma cell dyscrasia, including monoclonal gammopathy of 
undetermined significance, multiple myeloma, Waldenstrom macroglobulimemia, and POEMS 
syndrome.42  Patients presented with eosinophilic fasciitis (5 cases), morphea (3 cases) or systemic 
scleroderma (2 cases).  In 5 cases, plasma cells were light chain restricted; none of the cases showed an 
atypical distribution or increase in number of plasma cells compared to typical eosinophilic fasciitis and 
morphea.  Seven other studies examined cutaneous involvement by multiple myeloma.5,15,28,41,48,70,71  
Papers with full histopathologic descriptions reported nodules to sheets of plasma cells.  With the 
exception of three cases that could not be determined, all cases with reported kappa and lambda IHC or 
ISH were light chain restricted.  In comparison to MZLs and other types of B-cell lymphomas and 
lymphoproliferative disorders, little has been examined in the realm of cutaneous plasma cell dyscrasias 
with respect to light chain restriction.  Nonetheless, the available studies highlight that examination of 
kappa and lambda light chains by IHC and ISH are useful in the evaluation of cutaneous plasma cell 
dyscrasias and associated scleroderma-like tissue reactions.  
The kappa to lambda ratio used to support a monoclonal process and diagnosis of lymphoma varied 
significantly, with some authors using a kappa to lambda ratio that overlapped with normal ratios 
(kappa:lambda >2.5-333,41or lambda:kappa ≥141) and others using a more pronounced ratio (kappa:lambda  
≥8-108-15,72 or lambda:kappa >3-108,10-18,72).  Still, other authors used an intermediate range (kappa:lambda 
>55,16-18 lambda:kappa >1.6-2:15,9,33). Unfortunately, many studies do not specify the kappa and lambda 
ratio that was used to determine light chain restriction.23-26,28-32,34-36,38-40,42-45,47-55,57-59,62-66,68-71,73  
Complicating matters, universally accepted standards for kappa to lambda ratios that signify light chain 
restriction and monotypia have not been established.  
While this review focuses on the utility of IHC and ISH for kappa and lambda light chains, these tests 
must be interpreted in the context of the patient’s clinical and other histopathological findings.  These 
studies are only one factor in arriving at the correct diagnosis.  Reactive processes have rarely been 
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reported to show light chain restriction. Therefore, light chain restriction may not be unequivocally 
diagnostic of lymphoma.1,9,16,20,27,33,41 Some of these reported cases, however, are described with a kappa: 
lambda ratio within normal limits,33,41 and some may represent a lymphoma in evolution.9,33,41  For 
example, Sjogren’s syndrome may rarely display light chain restricted B cells and plasma cells without 
the development of lymphoma.9  Similarly, cutaneous plasmacytosis has been reported to rarely show 
light chain restriction.12 These cases may represent an exaggeration of normal B cell selection that occurs 
in response to an immune stimulus.20  Unusual B-cell lymphomas or plasma cell neoplasms may include 
separate kappa and lambda-positive clones that mimic a normal kappa to lambda ratio.30,76,77 Conversely, 
neoplastic B cells and plasma cells may not show light chain restriction by IHC or ISH.11,15,32,35,50,61  In 
some challenging cases, additional studies may be needed to assess clonality.33,41  
FC is of limited utility for small skin tumors.  However, it is generally an important tool in the evaluation 
of hematopoietic neoplasms and can also be used to evaluate light chain restriction in atypical cutaneous 
lymphoid infiltrates.  FC detects light chains on the surface and/or in the cytoplasm of B cells and detects 
cytoplasmic light chains in plasma cells.  Examination of cytoplasmic proteins requires a permeabilization 
procedure.  FC can be performed on skin biopsies, including punch biopsies and requires fairly rapid 
transport of fresh tissue to the flow cytometry laboratory (within 4-6 hours) in Roswell Park Memorial 
Institute (RPMI) media.  Gentle mincing/grinding of the tissue followed by filtration provide optimal 
results.5,64,76 Cells are then combined with fluorescently-labelled kappa and lambda antibodies and the 
specimen is examined using the flow cytometer.  If there are sufficient cells, FC allows the assessment of 
additional antigens on a given cell and it also assists in the recognition of dim antigen expression.  It is 
reported to be more sensitive than IHC/ISH5,6,50,64,76 and IgH gene rearrangement studies5,64,76 at 
recognizing a clonal B-cell population.  In comparison to IHC/ISH with a sensitivity of 37-55% and IgH 
gene rearrangement studies with a sensitivity of 39-43%, FC has a sensitivity of 68-100%.5,64,76  However, 
FC has some drawbacks.  It requires fresh tissue, special RPMI media, and rapid processing, and it does 
not include morphologic examination.  A second biopsy is therefore often required for subclassification of 
the lymphoma.  Sparse lymphoma infiltrates may not have sufficient neoplastic cells for FC studies,5,64 
and large, fragile cells as seen in DLBCL or FCL may not survive processing.5  As cutaneous marginal 
zone lymphomas may show restricted plasma cells only in the deepest portion of the lesion,13 flow 
cytometry theoretically could give false negative results in superficial biopsies.  Surface light chain 
assessment is not optimal for assessing plasma cells, and plasma cells may be underrepresented on flow 
cytometry, complicating evaluation of lymphomas with significant plasmacytic differentiation.5  Finally, 
FC laboratories vary in familiarity and technique in the evaluation of skin biopsies.   
Gene rearrangement studies examining IGH or IGK/IGL are also helpful in the evaluation of a possible 
cutaneous lymphoma or plasma cell neoplasm.  This topic has recently been reviewed.77  In summary, 
these studies help to support a diagnosis of lymphoma, but may be limited by insufficient or low-quality 
DNA, variability in the annealing of primer sets to the target sequences, somatic hypermutation, clonal 
heterogeneity, or variability/difficulty in the interpretation of monoclonal peaks.77-80  Consequently, 
monoclonal gene rearrangements may be found in lesions that do not meet other clinical or 
histopathologic features of a lymphoma,5,17,27,40,64 and neoplastic B-cell and plasma cell populations may 
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not be recognized as monoclonal.  These studies may miss clonal B-cell populations in as many as 50% of 
cases.81  Gene rearrangement studies are best interpreted in the context of a case assessed in its entirety. 
Next generation sequencing (NGS) is emerging as a tool for detection of clonal immunoglobulin light 
chain gene rearrangement studies.79  Although more studies are needed, this technique may be more 
sensitive at recognizing a monoclonal B-cell population, even in low density, poor quality samples.  In 
addition, NGS can be used to simultaneously assess multiple proteins important for diagnosis or 
prognosis.77,80 
In summary, there are several well-supported scenarios for the use of IHC and ISH for kappa and lambda 
light chains in the literature; however, important gaps in our knowledge remain.  Specifically, a standard 
kappa:lambda threshold for determining light chain restriction in cutaneous lesions is not defined.  There 
is an unclear relationship between light chain restriction (i.e. monotypism) and monoclonality assessed by 
gene rearrangement studies, although these often co-occurred in the few studies that examined both.  
Finally, there is a lack of guidance on the sequential or concurrent utility of kappa/lambda light chain 
expression by IHC/ISH, flow cytometry, IGH and IGK/IGL gene rearrangement or NGS in the diagnosis 
and evaluation of cutaneous lymphoid infiltrates that are concerning for lymphoma. Upcoming 
recommendations from the ASDP AUC committee will be published separately and aim to provide 
guidance on the use of IHC and ISH to detect light chain restriction and utility of these tests in diagnostic 
dermatopathology.  Importantly, there are pitfalls in the clinical, histopathologic, immunophenotypic, and 
genetic analysis of these cases, and accurate diagnosis relies upon a thorough assessment of the features 
of the case as a whole. 
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Figure Legends: 
Figure 1:  Primary cutaneous marginal zone lymphoma.  Sections show a dense lymphoid infiltrate with a 
grenz zone and numerous plasma cells (Figure 1A, B, 100X, 200X).  IHC for kappa reveals numerous 
kappa-positive cells (Figure 1C, 100X), while IHC for lambda reveals few scattered cells (Figure 1D, 
100X) with a kappa:lambda of >10:1.  Similarly, kappa ISH marks numerous cells (Figure 1E, 100X), 
while lambda ISH reveals rare cells (Figure 1F, 100X).    
Figure 2:  A dense, reactive infiltrate of plasma cells.  Sections show psoriasiform epidermal hyperplasia 
with numerous associated plasma cells (Figure 2A,B, 40X, 100X).  Kappa IHC reveals kappa-positive 
cells (Figure 2B, 100X) and lambda IHC shows slightly fewer lambda-positive cells (Figure 2C, 100X) 
for a kappa:lambda of approximately 2:1.  ISH similarly shows a slight predominance of kappa (Figure 
2D, 100X) compared to lambda (Figure 2E, 100X).  
 
Table Legends: 
Table 1: Summary of articles assessing kappa and lambda immunohistochemistry and in situ 
hybridization in the evaluation of an atypical cutaneous lymphoid infiltrate. 
Supplementary Table:  Synopsis of articles from 1967-2018 assessing kappa and lambda 
immunohistochemistry (IHC) and in situ hybridization (ISH) in cutaneous lymphoid infiltrates in the 
English language.  CLH – cutaneous lymphoid hyperplasia; RLH – reactive lymphoid hyperplasia; PC 
DLBCL – primary cutaneous diffuse large B-cell lymphoma; DLBCL – diffuse large B-cell lymphoma; 
PCDLBCL-LT – primary cutaneous diffuse large B-cell lymphoma, leg type; LBCL – large B-cell 
lymphoma, PCDLBCL – primary cutaneous diffuse large B-cell lymphoma; MZL – marginal zone 
lymphoma; PCMZL – primary cutaneous marginal zone lymphoma; EMZL – extranodal marginal zone 
lymphoma; CMZL – cutaneous marginal zone lymphoma; SCMZL – secondary cutaneous MZL; CBCL- 
cutaneous B-cell lymphoma; FCL – follicle center lymphoma; PCFCL – primary cutaneous follicle center 
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lymphoma; SCFCL – secondary cutaneous follicle center lymphoma; FL – follicular lymphoma; CLL – 
chronic lymphocytic leukemia; SCSCL – secondary cutaneous small cell lymphoma, SLL – small 
lymphocytic lymphoma; POEMS – polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, 
skin changes; MM – multiple myeloma;  PTCL, NOS – peripheral T-cell lymphoma, not otherwise 
specified; MF – mycosis fungoides; EBV – Epstein Barr Virus; HHV8 – Human Herpes Virus 8; FFPE – 
formalin fixed, paraffin embedded; FS – frozen section; PCR-polymerase chain reaction; IgH – 
immunoglobulin heavy chain; BRISH – bright field RNA in situ hybridization, mRNA – messenger 
ribonucleic acid; RPR – rapid plasma reagin; ANA – antinuclear antibody; HIV – human 
immunodeficiency virus. 
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Table 1:   
Total Number of Articles 63 
Breakdown by IHC and/or ISH  
     IHC 44 
     ISH 9 
     IHC and ISH 10 
Breakdown by specimen processing  
     Frozen 2 
     Formalin fixed paraffin embedded (FFPE) 49 
     Frozen and FFPE 5 
     FFPE and glutaraldehyde fixed paraffin embedded 1 
     FFPR and Zenker’s fixed paraffin embedded 1 
     FFPE and B5 fixed paraffin embedded 1 
     FFPE and B5 fixed paraffin embedded and frozen 1 
     Not specified 3 
Breakdown by Diagnosis  
     Cutaneous B-cell lymphoma, not further specified 2 
     Marginal zone lymphoma 39 
     Primary Cutaneous marginal zone lymphoma* 26 
     Follicle center lymphoma  11 
     Diffuse large B-cell lymphoma  8 
     Diffuse large B-cell lymphoma, leg type 5 
     Chronic lymphocytic leukemia/small lymphocytic lymphoma  7 
     Mantle Cell Lymphoma  2 
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     Lymphoplasmacytic lymphoma 2 
     Plasmablastic lymphoma 1 
     Plasma cell dyscrasias, including plasmacytoma   8 
     Multiple myeloma  7 
     Lymphoid hyperplasia, cutaneous and mucosal 13 
     Cutaneous plasmacytosis 5 
     Connective tissue disease 3 
     IgG4-related disease  2 
     Acrodermatitis chronica atrophicans 1 
     Zoon’s balanitis 1 
     Allergic dermatitis 1 
     Rosacea 1 
     Lichen planus 1 
     Syphilis 1 
     Plasma cell rich infiltrates around epithelial dysplasia/neoplasia 1 
     Secondary cutaneous B-cell lymphoma (not specified above) 5 
* Includes lesions termed immunocytomas, amyloidomas, primary cutaneous plasmacytomas and 
cutaneous follicular lymphoid hyperplasia with monotypic plasma cells examined alone or in 
combination with other lymphomas 
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